

REMARKS

Introductory Comments:

Claims 4-8, 11, 12, and 17-20 were examined in the Office Action dated October 4, 2007.

Claims 4-8, 11, 12, and 17-20 were rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite.

Claims 4-8, 11, 12, and 17-20 were rejected under the nonstatutory obviousness-type double patenting as being unpatenable over U.S. Patent no. 7,105,308 in view of US Patent No. 6,365,362.

Claims 4-8, 11, 12, and 17-20 were rejected under the nonstatutory obviousness-type double patenting as being unpatenable over U.S. Patent no. 7,135,300 in view of US Patent No. 6,365,362.

SUPPORT FOR AMENDMENTS

Claim 4 has been amended to recite that the cell surface antigen is in the protein-protein complex. The amendment finds support throughout the specification, such as, for example, the claims as originally filed.

Accordingly, no new matter has been added by way of this amendment and the entry thereof is respectfully requested.

REJECTIONS OF THE CLAIMS UNDER 35 U.S.C. §112

The Examiner rejected claims 4-8, 11, 12, and 17-20 under 35 U.S.C. §112, second paragraph, as allegedly being indefinite because it was said to be not clear if the cell surface antigen is one of the proteins in the protein-protein complex. The applicants have amended

claim 4 to recite that the antigen is on one of the proteins in the protein-protein complex. The Examiner is therefore respectfully requested to withdraw the rejection.

OBIOUSNESS-TYPE DOUBLE PATENTING

(a) The Examiner rejected claims 4-8, 11, 12, and 17-20 under the nonstatutory obviousness-type double patenting as being unpatenable over U.S. Patent No. 7,105,308 in view of US Patent No. 6,365,362. The applicants are attaching a terminal disclaimer over the U.S. Patent No. 7,105,308. The Examiner is therefore respectfully requested to withdraw the rejection.

(b) The Examiner rejected claims 4-8, 11, 12, and 17-20 under the nonstatutory obviousness-type double patenting as being unpatenable over U.S. Patent No. 7,135,300 in view of US Patent No. 6,365,362. The applicants are attaching a terminal disclaimer over the U.S. Patent No. 7,135,300. The Examiner is therefore respectfully requested to withdraw the rejection.

CONCLUSION

Applicants respectfully submit that the claims define an invention that is patentable over the art, and a notice of allowance is earnestly solicited. If the Examiner has any questions concerning this Response, the Examiner is invited to telephone Applicants' representative at (650) 335-7818.

Respectfully submitted,
Kirakossian et al.

Dated: March 4, 2008

By: /Narinder Banait/

Narinder S. Banait, Reg. No.: 43,482
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (650) 335-7818
Fax.: (650) 938-5200